Clinical Trial: Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) Nephropathy

U.S., May 27 -- ClinicalTrials.gov registry received information related to the study (NCT07606352) titled 'Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) Nephropathy' on May 07.

Brief Summary: This is a multicenter, randomized, double-blind, placebo controlled Phase IIb study to explore the efficacy and safety of STL303 capsules in IgAN patients. About 15 patients dignosed with primary IgAN will be enrolled and randomized to three cohorts and take different dosage of STL303 or placebo capsules orally according to protocol.

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: IgAN

Intervention: DRUG: STL303

STL303 arm participants will receive a specific dose of STL303

DRUG: STL303

STL3...